- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07573839
An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion
1 mei 2026 bijgewerkt door: Jun CHEN, Shanghai Mental Health Center
Bipolar disorder (BD) has become a significant public health problem with complex clinical manifestations, difficult treatment, and poor prognosis.
However, there is still a lack of effective biological markers for diagnosing and predicting recurrence.
Sentiment analysis computing usually refers to using machine equipment to classify, identify, interpret, and imitate human emotions.
However, current multi-modal emotion analysis research is mainly based on one or two modalities.
Due to the diversity and complexity of patients' emotional expressions, this single- and dual-modal information analysis is far from enough for accurate discrimination of emotional symptoms.
Only emotion analysis technology based on multi-modal feature fusion can make more precise and effective judgments.
The current project is based on our previous research on cognitive neuroimaging and big data analysis of bipolar disorder.
The investigators plan to enroll 200 BD patients who meet DSM-5 diagnostic criteria and 200 healthy controls.
The investigators will use sentiment analysis technology with multi-modal feature fusion (text data, audio and visual modalities, eye movements, and electrophysiology) to identify BD recurrence.
Biological markers for risk prediction and an algorithm model for joint judgment of multi-source information will be established to analyze the characterization data.
The effectiveness of this recurrence prediction model will be further verified and optimized through a large-sample, prospective cohort study design.
It is hoped that it can provide a new method for predicting the recurrence risk of BD patients.
In the near future, clinical decision-making aids based on this auxiliary method can be developed, and the translational application value of clinical diagnosis and treatment can be explored.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Studietype
Observationeel
Inschrijving (Geschat)
400
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Shanghai, China
- Werving
- Shanghai Mental Health Center
-
Contact:
- Jun CHEN
- Telefoonnummer: 021-34773523
- E-mail: doctorcj2010@gmail.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Ja
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
1. patients with bipolar disorder; 2. healthy controls.
Beschrijving
Patients group inclusion criteria:
- Patients who have previously met or currently meet the diagnostic criteria for bipolar disorder according to DSM-5, whose condition and treatment are currently stable, and who cooperate with the assessment;
- Age ≥18 years, <65 years;
- Han Chinese ethnicity;
- Sufficient visual and auditory abilities to complete the necessary examinations for the study;
- Understanding the study content and signing the informed consent form. If the patient is unable to sign the informed consent form personally due to low education level or other reasons, it may be signed by a relative or guardian on their behalf.
exclusion criteria:
- The presence of intellectual disability or other conditions that significantly affect the patient's current mental state;
- the patient has a serious or unstable physical illness, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension (including untreated or uncontrolled hypertension), malignant tumors, immunodeficiency, and blood glucose levels higher than 12 mmol/L; or other diseases that may interfere with the test assessment (abnormal indicators more than twice the normal value).
Healthy controls group inclusion criteria:
- Age ≥ 18 years, < 65 years;
- Han Chinese ethnicity;
- Gender matched to the patient group;
- Sufficient visual and auditory ability to complete the necessary examinations for the study;
- Understanding of the study content and signing of informed consent;
- No family history of mental illness. exclusion criteria:
- Individuals with a mental disorder conforming to DSM-5, or those with suspicious mental symptoms but not meeting the diagnostic criteria;
- Individuals with severe physical illness that makes it difficult to complete the necessary examinations.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
gezonde controle
|
This is an observational study with no intervention.
|
|
patients with bipolar disorder
|
This is an observational study with no intervention.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The recurrence status of patients with bipolar disorder
Tijdsspanne: 1 year, patients will be followed-up every 3 months and healthy controls will be assessed only at baseline
|
The presence and the type of a relapse will be diagnosed by psychiatrists and assessed using DSM-5 by study assistants.
Furthermore, predictive models for recurrence risk of bipolar disorder will be constructed, with adopting the Area Under Curve (AUC) of Receiver Operating Characteristic (ROC) and other measurements to evaluate the performance of constructed models.
|
1 year, patients will be followed-up every 3 months and healthy controls will be assessed only at baseline
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 april 2026
Primaire voltooiing (Geschat)
1 december 2027
Studie voltooiing (Geschat)
1 december 2027
Studieregistratiedata
Eerst ingediend
13 april 2026
Eerst ingediend dat voldeed aan de QC-criteria
1 mei 2026
Eerst geplaatst (Werkelijk)
7 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
7 mei 2026
Laatste update ingediend die voldeed aan QC-criteria
1 mei 2026
Laatst geverifieerd
1 mei 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 8247054596
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .